Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty

American Journal of Cardiology

Volumn 82, Issue 8 SUPPL. 1, 1998, Pages

  Bittl, John A ^a   Ahmed, Waqar H ^b  

^a Ocala Heart and Vascular Institute   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; HIRULOG;

ADULT; AGED; ANTICOAGULATION; BLEEDING; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; WOUND CLOSURE;

EID: 0031789076     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9149(98)00760-7     Document Type: Article

References (32)

1. Fuster V, Badimon JJ, Badimon L. Clinical-pathological correlations of coronary disease progression and regression. Circulation 1992;86(suppl III):III-1-III-11.
2. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part I: Heparin. Circulation 1994;89:1449-1468.
3. Wolfe MW, Roubin GS, Schweiger M, Isner JM, Ferguson JJ, Cannon AD, Cleman M, Cabin H, Leya F, Bonan R, Strony J, Adelman B, Bittl JA, on behalf of the Heparin Registry Investigators. Length of hospital stay and complications after percutaneous transluminal coronary angioplasty. Clinical and procedural predictors. Circulation 1995;92:311-319.
4. Ellis SG, Omoigui N, Bittl JA, Lincoff M, Wolfe MW, Howell G, Topol EJ. Analysis and comparison of operator-specific outcomes in interventional cardiology. From a multicenter database of 4860 quality-controlled procedures. Circulation 1996;93:431-439.
5. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon MB, Williams DO, King SB, III, Mark DB, Isner JM, Holmes DR, Ellis SG, Lee KL, Keeler G, Berdan LG, Hinohara T, Califf RM, on behalf of the CAVEAT Study Group. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. N Engl J Med 1993;329:221-227.
6. Adelman AG, Cohen EA, Kimball BP, Bonan R, Ricci DR, Webb JG, Laramee L, Barbeau G, Traboulsi M, Corbett BN, Logan AG, Schwartz L, Sykora K, Slaughter P. A comparison of coronary atherectomy with coronary angioplasty for lesions of the left anterior descending coronary artery. N Engl J Med 1993;329:228-233.
7. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M-A, for the BENESTENT Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495.
8. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricchi D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish DS, Colombo A, Brinker J, Moses J, Shaknovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S, for the Stent Restenosis Study Investigators. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
9. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
10. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
11. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-1435.
12. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, March KC, Leachman DR. Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1994;23:1061-1065.
13. Narins CR, Hillegass WB Jr, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Relation between activated clotting time during angioplasty and abrupt closure. Circulation 1996;93:660-671.
14. Frierson JH, Dimas AP, Simpfendorfer CC, Pearce G, Miller M, Franco I. Is aggressive heparinization necessary for elective PTCA? Cathet Cardiovasc Diagn 1993;28:279-282.
15. Aguirre FV, Ferguson JJ, Blankenship JC, Pieper KS, Taylor M, Harrington RA, Rund M, Caracciolo EA, Donohue TJ, Califf RM, Lincoff AM, Tcheng JE, Topol EJ, for the IMPACT-II Investigators. Association of pre-intervention activated clotting times (ACT) and clinical outcomes following percutaneous coronary revascularization: results from the IMPACT-II Trials. (Abstr.) J Am Coll Cardiol 1996;27(suppl A):83A.
16. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J, Ganz P, Cohen MD, Raymond R, Fox I, Maraganore J, Adelman B. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. Circulation 1993;87:1622-1629.
17. Topol EJ, Fuster V, Harrington RA, Califf RM, Kleiman NS, Kereiakes DJ, Cohen M, Chapekis A, Gold HK, Tannenbaum MA, Rao AK, Debowey D, Schwartz D, Henis M, Chesebro J. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. Circulation 1994;89:1557-1566.
18. Serruys PW, Herrman J-PR, Simon R, Rutsch W, Bode C, Laarman G-J, van Dijk R, van den Bos AA, Umans VA, Fox KA, Close P, Deckers JW, for the HELVETICA Investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med 1995;333:757-763.
19. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B, for the Hirulog Angioplasty Study Investigators. Treatment with bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769.
20. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391.
21. Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP. Heparin neutralization by platelet-rich thrombi. Role of platelet factor 4. Circulation 1994;89:1523-1529.
22. Experience in the Coronary Drug Project. The prognostic importance of the electrocardiogram after myocardial infarction. Ann Intern Med 1972;77:677-689.
23. Zar JH. The normal distribution. In: Zar JH, ed. Biostatistical Analysis. Englewood Cliffs, NJ: Prentice-Hall, 1984:79-96.
24. Zar JH. Two-sample hypotheses. In: Zar JH, ed. Biostatistical Analysis. Englewood Cliffs, NJ: Prentice-Hall, 1984:122-149.
25. Glantz SA, Slinker BK. Regression with a qualitative dependent variable. In: Glantz SA, Slinker BK, eds. Primer of Applied Regression and Analysis of Variance. New York: McGraw-Hill, 1990:512-568.
26. Ryan TJ, Bauman WB, Kennedy JW, Kereiakes DJ, King SB III, McCallister BD, Smith SC Jr, Ullyot DJ. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1993;88:2987-3007.
27. Marmur JD, Merlini PA, Sharma SK, Khaghan N, Torre SR, Israel DH, Ardissino D, Ambrose JA. Thrombin generation in human coronary arteries after percutaneous transluminal balloon angioplasty. J Am Coll Cardiol 1994;24:1484-1491.
28. Gast A, Tschopp TB, Schmid G, Hilpert K, Ackermann J. Inhibition of clot-bound and free (fluid-phase thrombin) by a novel synthetic thrombin inhibitor (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagul Fibrinolysis 1994;5:879-887.
29. Carteaux JP, Gast A, Tschopp TB, Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 1995;91:1568-1574.
30. Roubin GS, Cannon AD, Agrawal SK, Macander PJ, Dean LS, Baxley WA, Breland J. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation 1992;85:916-927.
31. Detre KM, Holmes DR Jr, Holubkov R, Cowley MJ, Bourassa MG, Faxon DP, Dorros GR, Bentivoglio LG, Kent KM, Myler RK. Incidence and consequences of peri procedural occlusion. The 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990;82:739-750.
32. de Feyter PJ, van den Brand M, Laarman GJ, van Domburg R, Serruys PW, Suryapranata H, Laarman G. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty. Frequency, prediction, clinical course, management, and follow-up. Circulation 1991;83:927-936.